Organon Q1 revenue $1.46B (-4% YoY); declares $0.02 dividend; Sun Pharma merger pending

Organon & Co.

2026-Q1 EPS reported $0.55 revenue$1,460,000,000

Revenue $1.460B, down 4% as-reported, down 9% ex-FX; Women's Health -16%, Biosimilars +23%.
GAAP diluted EPS $0.55, Adjusted diluted EPS $0.71; Adjusted EBITDA $415M (28.4% margin).
Board declares quarterly dividend of $0.02/share, payable June 11 to holders of record May 11.
Pending all-cash merger with Sun Pharma expected to close early 2027; guidance and earnings calls suspended.
Net income $146M vs $87M YoY; cash and equivalents $1.12B, debt $8.57B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Organon & Co. reported quarter ended March 31, 2026 results: revenue $1.460 billion, net income $146 million, EPS $0.55.

Period: quarter ended March 31, 2026
Revenue: $1.460 billion
Net income: $146 million
EPS: $0.55
Result: reported results

Exact text from the filing

Organon Reports Results for the First Quarter Ended March 31, 2026 · First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. · First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. · First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%.

View on SEC.gov

1430 earnings releases filed in the last 30 days. Browse all earnings releases →

Organon & Co. filing history →

Source: SEC EDGAR

accession 0001104659-26-052165

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.